-
Latest News
Archives
Tag Archives: Prof Olav Mella
Norwegian Rituximab studies update
Helse Bergen blog post, 29 Sep 29017: RituxME B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome (“RituxME”) RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University … Continue reading
Posted in News
Tagged antibodies, Dr Oystein Fluge, Norway, Prof Olav Mella, rituximab, RituxME
Comments Off on Norwegian Rituximab studies update
New rituximab trial results from Norway
Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading
Posted in News
Tagged B-cell, Dr Oystein Fluge, Norway, Prof Olav Mella, rituximab, T-cell
Comments Off on New rituximab trial results from Norway
Cancer doctor Dagfinn Øgreid has treated ME patients with rituximab
Blog article: Offers private ME treatment with cancer drugs – scientists react, by Anne Grete Storvik, Nov 23 2015 in Dagensmedicin [ translated by Google translate] A private clinic in Sandnes offers treatment for ME with the cancer drug rituximab. Patients pay … Continue reading
Posted in News
Tagged autoimmune disorders, Dr Dagfinn Øgreid, Dr Oystein Fluge, immunomodulatory drug, Norway, Prof Olav Mella, rituximab
1 Comment
UK rituximab trial fundraising total almost reached
Invest in ME has announced the latest fundraising total for the rituximab/B-cell research, which is a great boost as the research team at UCL are about to visit and discuss the subject with Dr Fluge and Professor Mella in Haukeland University Hospital, … Continue reading
Posted in News
Tagged B-cell, Dr Oystein Fluge, IiME, Invest in ME, Prof Olav Mella, rituximab, UCL, University College London
Comments Off on UK rituximab trial fundraising total almost reached
Elevated autoantibodies found in CFS subgroup
Research highlights: β adrenergic and muscarinic acetylcholine receptor autoantibodies are elevated in a subset of patients with Chronic Fatigue Syndrome (CFS). Elevated autoantibodies in CFS correlate with elevated IgG1-3 subclass levels, thyreoperoxidase and ANA antibodies and T cell activation. In … Continue reading
Posted in News
Tagged autoantibodies, autoimmune disorders, Dr Oystein Fluge, Prof Olav Mella, Receptors, rituximab, subgroup, T-cell
Comments Off on Elevated autoantibodies found in CFS subgroup
Norwegian Rituximab trial update
The Norwegian multicenter Rituximab study begins The long-awaited Norwegian phase III study of Rituximab as a treatment for ME/CFS is now getting off the ground. The study is led by the oncologists Prof Olav Mella and Dr Øystein Fluge at … Continue reading
Posted in News
Tagged Dr Jo Cambridge, Dr Oystein Fluge, Norway, Prof Jonathan Edwards, Prof Olav Mella, rituximab
Comments Off on Norwegian Rituximab trial update
